naphazoline has been researched along with 2019 Novel Coronavirus Disease in 2 studies
Naphazoline: An adrenergic vasoconstrictor agent used as a decongestant.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fritzsching, B | 1 |
| Andreica, I | 1 |
| Guminski, B | 1 |
| Sokolar, J | 1 |
| Patru, A | 1 |
| Baraliakos, X | 1 |
| Braun, J | 1 |
1 review available for naphazoline and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Topics: Asthma; COVID-19; Humans; Naphazoline | 2022 |
1 other study available for naphazoline and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
[Threat of a SARS-CoV-2 endemic in a large hospital specialized in rheumatic diseases-relative all clear through consistent testing].
Topics: COVID-19; Germany; Hospitals; Humans; Naphazoline; Rheumatic Diseases; SARS-CoV-2 | 2021 |